Design and synthesis of glyco-peptides as anti-cancer agents targeting thrombin-protease activated receptor-1 interaction

Chem Commun (Camb). 2020 May 28;56(43):5827-5830. doi: 10.1039/d0cc01240h. Epub 2020 Apr 24.

Abstract

Thrombin activates protease-activated receptor-1 (PAR-1) through binding to exosite I and the active site to promote tumor growth. We have developed a new class of anti-cancer glyco-peptides to target exosite I selectively without affecting the active-site-mediated coagulation activity and showed the importance of glycans for the stability and anti-cancer activity of the glyco-peptides.

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Cell Line, Tumor
  • Drug Design
  • Glycopeptides / chemistry
  • Glycopeptides / pharmacology
  • Glycopeptides / therapeutic use*
  • Humans
  • Mice, SCID
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • Receptor, PAR-1 / metabolism*
  • Thrombin / chemistry
  • Thrombin / metabolism*

Substances

  • Antineoplastic Agents
  • Glycopeptides
  • Receptor, PAR-1
  • Thrombin